{"transactions":[{"id":932170,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:17:13.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":5.79,"underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0000905148-26-000312","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000312/form4.xml","form_type":"4"}},{"id":932169,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:17:13.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":9.18,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000312","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000312/form4.xml","form_type":"4"}},{"id":932168,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:17:13.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":11.35,"underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0000905148-26-000312","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000312/form4.xml","form_type":"4"}},{"id":932167,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:17:13.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0000905148-26-000312","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000312/form4.xml","form_type":"4"}},{"id":932166,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:17:13.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021."}],"balance_after":0,"derivative":{"exercise_price":12.24,"underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0000905148-26-000312","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000312/form4.xml","form_type":"4"}},{"id":1005073,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"shares":1105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":280.04,"expiration_date":"2031-06-25","underlying":"Common Stock","underlying_shares":1105},"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005072,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":303.79,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005071,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":false,"shares":5470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.45,"expiration_date":"2026-07-22","underlying":"Common Stock","underlying_shares":5470},"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005070,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":30,"price":490.9817,"value":14729.451,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive."}],"balance_after":2627,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005069,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":933,"price":489.9455,"value":457119.1515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive."}],"balance_after":2657,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005068,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":696,"price":489.094,"value":340409.424,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive."}],"balance_after":3590,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005067,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":2775,"price":487.494,"value":1352795.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive."}],"balance_after":4286,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005066,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":827,"price":486.7347,"value":402529.5969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive."}],"balance_after":7061,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005065,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":1008,"price":485.5368,"value":489421.0944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive."}],"balance_after":7888,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005064,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":1931,"price":484.7773,"value":936104.9663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive."}],"balance_after":8896,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005063,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":2069,"price":483.4074,"value":1000169.9106,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive."}],"balance_after":10827,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005062,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":1284,"price":482.4122,"value":619417.2648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive."}],"balance_after":12896,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005061,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":3259,"price":481.1276,"value":1567994.8484,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive."}],"balance_after":14180,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005060,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"sale","planned":false,"acquired":false,"shares":1763,"price":480.2397,"value":846662.5911,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":17439,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005059,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":1105,"price":280.04,"value":309444.2,"ownership":{"direct":true},"balance_after":19202,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005058,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":303.79,"value":3037900.0,"ownership":{"direct":true},"balance_after":18097,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1005057,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-07T21:20:22.000Z","date":"2025-11-05","kind":"exercise","planned":false,"acquired":true,"shares":5470,"price":9.45,"value":51691.5,"ownership":{"direct":true},"balance_after":8097,"source":{"system":"sec-edgar","filing":"0001628280-25-050668","document":"wk-form4_1762550418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025050668/wk-form4_1762550418.xml","form_type":"4"}},{"id":1065662,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":16.46,"expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065661,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":896,"price":368.5557,"value":330225.9072,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.13 to $368.98, inclusive."}],"balance_after":2627,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065660,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":1104,"price":367.6311,"value":405864.7344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.115 to $368.05, inclusive."}],"balance_after":3523,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065659,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":600,"price":366.1383,"value":219682.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.22, inclusive."}],"balance_after":4627,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065658,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":2567,"price":365.3264,"value":937792.8688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.91 to $365.77, inclusive."}],"balance_after":5227,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065657,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":2516,"price":364.2399,"value":916427.5884,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.88 to $364.87, inclusive."}],"balance_after":7794,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065656,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":2317,"price":363.4072,"value":842014.4824,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.87 to $363.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":10310,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1065655,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-15T22:04:57.000Z","date":"2025-08-15","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":16.46,"value":164600.0,"ownership":{"direct":true},"balance_after":12627,"source":{"system":"sec-edgar","filing":"0001210238-25-000005","document":"wk-form4_1755295493.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000121023825000005/wk-form4_1755295493.xml","form_type":"4"}},{"id":1102936,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T20:45:22.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":1290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date."}],"balance_after":1290,"derivative":{"exercise_price":285.73,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":1290},"source":{"system":"sec-edgar","filing":"0001628280-25-032863","document":"wk-form4_1750797916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025032863/wk-form4_1750797916.xml","form_type":"4"}},{"id":1102935,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T20:45:22.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":2627,"source":{"system":"sec-edgar","filing":"0001628280-25-032863","document":"wk-form4_1750797916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025032863/wk-form4_1750797916.xml","form_type":"4"}},{"id":1113254,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T19:15:46.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":26550,"derivative":{"exercise_price":5.79,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26550},"source":{"system":"sec-edgar","filing":"0001104659-25-059042","document":"tm2517800-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925059042/tm2517800-7_4seq1.xml","form_type":"4"}},{"id":1238950,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":4530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":5470,"derivative":{"exercise_price":9.45,"expiration_date":"2026-07-22","underlying":"Common Stock","underlying_shares":4530},"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238949,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":9470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":65.06,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":9470},"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238948,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":111.06,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238947,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":216,"price":360.0662,"value":77774.2992,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.99 to $360.17, inclusive."}],"balance_after":1912,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238946,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":2024,"price":359.2106,"value":727042.2544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.94 to $359.84, inclusive."}],"balance_after":2128,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238945,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":3548,"price":358.3311,"value":1271358.7428,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.91 to $358.83, inclusive."}],"balance_after":4152,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238944,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":2038,"price":357.2664,"value":728108.9232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.83 to $357.79, inclusive."}],"balance_after":7700,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238943,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":2791,"price":356.5089,"value":995016.3399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.83 to $356.79, inclusive."}],"balance_after":9738,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238942,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":8545,"price":355.079,"value":3034150.055,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.79 to $355.78, inclusive."}],"balance_after":12529,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238941,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":238,"price":353.8345,"value":84212.611,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.78 to $354.50, inclusive."}],"balance_after":21074,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238940,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":500,"price":351.99,"value":175995.0,"ownership":{"direct":true},"balance_after":21312,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238939,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"sale","planned":false,"acquired":false,"shares":100,"price":351.0073,"value":35100.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":21812,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238938,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":4530,"price":9.45,"value":42808.5,"ownership":{"direct":true},"balance_after":21912,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238937,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":9470,"price":65.06,"value":616118.2,"ownership":{"direct":true},"balance_after":17382,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1238936,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-28T21:30:17.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":6000,"price":111.06,"value":666360.0,"ownership":{"direct":true},"balance_after":7912,"source":{"system":"sec-edgar","filing":"0001628280-25-009076","document":"wk-form4_1740778208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009076/wk-form4_1740778208.xml","form_type":"4"}},{"id":1468300,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-28T01:45:13.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":1105,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":1105,"derivative":{"exercise_price":280.04,"expiration_date":"2031-06-25","underlying":"Common Stock","underlying_shares":1105},"source":{"system":"sec-edgar","filing":"0000950170-24-078754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024078754/ownership.xml","form_type":"4"}},{"id":1468299,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-28T01:45:13.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":1912,"source":{"system":"sec-edgar","filing":"0000950170-24-078754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024078754/ownership.xml","form_type":"4"}},{"id":1488306,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:05:11.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":9.18,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-24-069065","document":"tm2416582-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924069065/tm2416582-1_4seq1.xml","form_type":"4"}},{"id":1550624,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":false,"shares":11212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":11212},"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550623,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":1277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":11212,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":1277},"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550622,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":100.45,"expiration_date":"2024-06-27","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550621,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F18","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":10000,"derivative":{"exercise_price":9.45,"expiration_date":"2026-07-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550620,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":7,"price":249.05,"value":1743.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550619,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":193,"price":248.4887,"value":47958.3191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.01 to $249.00, inclusive."}],"balance_after":1205,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550618,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":246.8805,"value":24688.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.87 to $246.95, inclusive."}],"balance_after":1398,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550617,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":567,"price":246.2028,"value":139596.9876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.77 to $246.35, inclusive."}],"balance_after":1498,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550616,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":2080,"price":244.965,"value":509527.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.73 to $245.52, inclusive."}],"balance_after":2065,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550615,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":7048,"price":244.2722,"value":1721630.4656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.73 to $244.71, inclusive."}],"balance_after":4145,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550614,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":1217,"price":243.2823,"value":296074.5591,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.59 to $243.54, inclusive."}],"balance_after":11193,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550613,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-02","kind":"exercise","planned":true,"acquired":true,"shares":11212,"price":105.08,"value":1178156.96,"ownership":{"direct":true},"balance_after":12410,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550612,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":274,"price":266.9052,"value":73132.0248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.73 to $267.21, inclusive."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550611,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":700,"price":265.3557,"value":185748.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.04 to $265.64, inclusive."}],"balance_after":1472,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550610,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":116,"price":264.7343,"value":30709.1788,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.00 to $264.85, inclusive."}],"balance_after":2172,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550609,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":143,"price":263.0816,"value":37620.6688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.00 to $263.98, inclusive."}],"balance_after":2288,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550608,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":841,"price":262.1797,"value":220493.1277,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.95 to $262.82, inclusive."}],"balance_after":2431,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550607,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":259.13,"value":51826.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.11 to $259.15, inclusive."}],"balance_after":3272,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550606,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":2104,"price":258.2412,"value":543339.4848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.02 to $258.93, inclusive."}],"balance_after":3472,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550605,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":2790,"price":257.3262,"value":717940.098,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.01 to $258.00, inclusive."}],"balance_after":5576,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550604,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":7411,"price":256.4904,"value":1900850.3544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.01 to $256.99, inclusive."}],"balance_after":8366,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550603,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":6698,"price":255.6165,"value":1712119.317,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.01 to $256.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":15777,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550602,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":1277,"price":105.08,"value":134187.16,"ownership":{"direct":true},"balance_after":22475,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550601,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":100.45,"value":1004500.0,"ownership":{"direct":true},"balance_after":21198,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1550600,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:44:23.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":9.45,"value":94500.0,"ownership":{"direct":true},"balance_after":11198,"source":{"system":"sec-edgar","filing":"0000899243-24-000245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924324000245/doc4.xml","form_type":"4"}},{"id":1850114,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T22:41:10.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":1198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date."}],"balance_after":1198,"source":{"system":"sec-edgar","filing":"0000899243-23-016056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924323016056/doc4.xml","form_type":"4"}},{"id":1865091,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T08:00:47.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":14100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":14100,"derivative":{"exercise_price":11.35,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":14100},"source":{"system":"sec-edgar","filing":"0001104659-23-068334","document":"tm2317752-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465923068334/tm2317752-1_4seq1.xml","form_type":"4"}},{"id":2050694,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050693,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7.27,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050692,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7.52,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050691,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7.6,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050690,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":22.7,"expiration_date":"2028-06-17","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050689,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":7785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":7785},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050688,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":6402,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":9.2,"expiration_date":"2026-05-26","underlying":"Common Stock","underlying_shares":6402},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050687,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2025-05-28","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050686,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":2515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":16.1,"expiration_date":"2025-04-02","underlying":"Common Stock","underlying_shares":2515},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050685,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":15.7,"expiration_date":"2024-06-19","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050684,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":1250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":25.9,"expiration_date":"2023-05-29","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2050683,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-19T17:19:11.000Z","date":"2023-01-19","kind":"disposition_to_issuer","acquired":false,"shares":375,"price":15,"value":5625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration."}],"balance_after":375,"source":{"system":"sec-edgar","filing":"0000899243-23-002195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000089924323002195/doc4.xml","form_type":"4"}},{"id":2183883,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T18:55:00.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8994,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1210238/000089924322028858/doc4.xml","form_type":"4"}},{"id":2183882,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T18:55:00.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8060,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."}],"balance_after":8994,"source":{"system":"sec-edgar","filing":"0000899243-22-028858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1210238/000089924322028858/doc4.xml","form_type":"4"}},{"id":2225843,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-21T10:30:29.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":9470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":9470,"derivative":{"exercise_price":65.06,"expiration_date":"2025-06-16","underlying":"Common Stock","underlying_shares":9470},"source":{"system":"sec-edgar","filing":"0000899243-22-023234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924322023234/doc4.xml","form_type":"4"}},{"id":2225310,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T08:33:29.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":3,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-072753","document":"tm2218796-6_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922072753/tm2218796-6_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-06-09"}},{"id":2237675,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-09T18:00:19.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service."}],"balance_after":8333,"derivative":{"exercise_price":2.99,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001104659-22-069759","document":"tm2218033-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922069759/tm2218033-6_4seq1.xml","form_type":"4"}},{"id":2238971,"issuer":{"id":120602,"kind":"organization","name":"AVEO PHARMACEUTICALS, INC.","symbol":"AVEO"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-08T16:58:57.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twelve equal monthly installments beginning July 1, 2021, subject to the Reporting Person's continued service to the Company."}],"balance_after":22500,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-06","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001628280-22-016604","document":"wf-form4_165472191761209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325879/000162828022016604/wf-form4_165472191761209.xml","form_type":"4"}},{"id":2263343,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T16:30:40.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":41006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":41006,"derivative":{"exercise_price":0.56,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":41006},"source":{"system":"sec-edgar","filing":"0000899243-22-018843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1210238/000089924322018843/doc4.xml","form_type":"4"}},{"id":2263342,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-05-19T16:30:40.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":8994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 8,994 restricted stock units (\"RSUs\") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":17054,"source":{"system":"sec-edgar","filing":"0000899243-22-018843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1210238/000089924322018843/doc4.xml","form_type":"4"}},{"id":2644477,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T11:54:00.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options are scheduled to vest on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.33,"exercise_date":"2022-07-01","expiration_date":"2031-07-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001457612-21-000080","document":"wf-form4_162524122536579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761221000080/wf-form4_162524122536579.xml","form_type":"4"}},{"id":2661591,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":68889,"kind":"person","name":"BATE KENNETH","position":1,"cik":"0001210238","reported_name":"BATE KENNETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T12:02:03.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":12489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date."}],"balance_after":12489,"derivative":{"exercise_price":105.08,"expiration_date":"2024-06-17","underlying":"Common Stock","underlying_shares":12489},"source":{"system":"sec-edgar","filing":"0000899243-21-024665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321024665/doc4.xml","form_type":"4"}}],"next_cursor":"2021-06-21T12:02:03.000000Z,2661591"}